H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Biogen Inc (NASDAQ:BIIB) on Monday, setting a price target of $289, which is approximately 12.40% below the present share price of $329.9.
Fein expects Biogen Inc to post earnings per share (EPS) of $4.47 for the fourth quarter of 2020.
The current consensus among 27 TipRanks analysts is for a Moderate Buy rating of shares in Biogen, with an average price target of $315.14.
The analysts price targets range from a high of $450 to a low of $244.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $3.38 billion and a net profit of $1.06 billion. The company's market cap is $50.61 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 4.8% and a 42.86% success rate.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp (OTC:SHCAY) in 1978 and is headquartered in Cambridge, MA.